Cash available vs expensesLooking at the Q2 financials they had approximately 1M in cash available at the end of the QTR. They spent over 900K during Q2 so, if the spending keeps going at the same pace they'll be out of money by end of Q3.
Despite the fact that the sales of the STEM Animal division allowed them to have a cleaner balance sheet it might not stay clean for very long if the sales of Revyve doesn't ramp up quickly.
They will also have to spend some money on the UofMiami acne trial which is coming soon, that will put some more pressure on the cash they have.
P.S. I believe that all expenses related to the DispersinB phase1 trial is going to be taken care of by the US Dept. of Defense.
The above are 'food for thoughts'...